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Objective: Open revascularization (OR) has been the treatment of choice for chronic mesenteric ischemia (CMI) for many
years, but endovascular revascularization (EV) has been increasingly used with good short-term results. In this study, we
evaluated the comparative effectiveness and cost-effectiveness of EV and OR in patients with CMI refractory to con-
servative management.
Methods: A Markov-state transition model was developed using TreeAge Pro 2012 (TreeAge Inc, Williamstown, Mass) to
simulate a hypothetical cohort of 10,000 65-year-old female patients with CMI requiring treatment with either OR or
EV. Data for the model, including perioperative and long-term overall mortality risks, disease-speciﬁc mortality risks,
complications, and reintervention and patency rates, were retrieved from original studies and systematic reviews about
CMI. Costs were analyzed with the 2013 Medicare database. Outcomes evaluated were quality-adjusted life-years
(QALYs), costs from the health care perspective, and the incremental cost-effectiveness ratio. Extensive sensitivity ana-
lyses were performed and different clinical scenarios evaluated. Probabilistic sensitivity analysis was performed to assess
robustness of the model.
Results: For a reference-case 65-year-old female patient with CMI and an average risk for operation, EV is preferred with
10.03 QALYs (95% credibility interval [CI], 9.76-10.29) vs 9.59 after OR (95% CI, 9.29-9.87). The difference is
comparable to 5 months in perfect health: 0.44 QALY (95% CI, 0.13-0.76). For 65-year-old men, this was 8.71 QALYs
(95% CI, 8.48-8.94) for EV vs 8.42 (95% CI, 8.14-8.63) for OR. Sensitivity analysis showed that for younger patients,
EV results in a higher increase in QALYs compared with older patients. Total expected reinterventions per patient are
1.70 for EV vs 0.30 for OR. Total expected health care costs for the reference-case patient were $39,942 (95% CI,
$28,509-$53,380) for OR and $38.217 (95% CI, $29,329-$48,309) for EV. For men, this was $39,375 (95% CI,
$28,092-$52,853) for OR and $35,903 (95% CI, $27,685-$45,597) for EV. For patients younger than 60 years, EV is a
more expensive treatment strategy compared with OR, but with an incremental cost-effectiveness ratio for EV of less than
$60,000/QALY. For patients 60 years and older, EV dominated OR as preferential treatment because effectiveness was
higher than for OR and costs were lower.
Conclusions: The results of this decision analysis model suggest that EV is favored over OR for patients with CMI in all age
groups. Although EV is associated with more expected reinterventions, EV appears to be cost-effective for all age
groups. (J Vasc Surg 2014;60:715-25.)Chronic mesenteric ischemia (CMI) is an uncom-
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://dx.doi.org/10.1016/j.jvs.2014.03.009usually limited in at least two of the three mesenteric ves-
sels before symptoms occur because of the presence of
extensive collateralization.1 CMI, or intestinal angina,
causes postprandial pain, usually within the ﬁrst hour,
which could lead to food aversion, malnutrition, and
weight loss.1,2 Ultimately, this may lead to acute bowel
infarction, potentially resulting in perforation, sepsis,
and subsequent death.3 For treatment of symptoms
and prevention of complications, revascularization is
usually required.4
Open revascularization (OR) of the visceral vessels,
including endarterectomy, direct reimplantation, and
bypass grafting, has been the treatment of choice for
many years.5 Endovascular revascularization (EV) was
described in 1980 and is now increasingly used.6 Since
2002, angioplasty or stenting of the visceral arteries has
been performed more frequently than OR,7 and several
large studies reported good short-term results.8,9 Unfortu-
nately, there is currently no level I evidence available
comparing these two CMI treatment modalities. Further-
more, most studies have focused on survival, patency rates,715
Fig 1. Simpliﬁed bubble diagram of the Markov state transition model for treatment of chronic mesenteric ischemia
(CMI). Each health state has a possible transition to itself that is not shown in this ﬁgure for clarity of the ﬁgure. The
dotted lines indicate the start of the intervention or reintervention. EV, Endovascular revascularization; OR, open
revascularization.
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ity of life (QoL) and costs are lacking. The primary goal of
this study was to compare effectiveness of EV and OR with
respect to quality-adjusted life-years (QALYs) for patients
with CMI refractory to conservative management by
means of a decision analysis. The secondary objective was
to determine the cost-effectiveness of the different treat-
ment strategies.
METHODS
A Markov cohort model was developed using Tree-
Age Pro 2012 (TreeAge Inc, Williamstown, Mass) to
simulate a hypothetical cohort of 10,000 65-year-old fe-
male patients with CMI refractory to conservative man-
agement and requiring an intervention. A Markov
cohort model is a convenient way to analyze the prog-
nosis for clinical problems with risks that change over
time. The Markov model assumes that a patient is always
in one of a ﬁnite number of discrete health states. All pos-
sibilities are modeled as transitions from one health state
to another. Each health state is assigned a QoL value
(utility), and the contribution of this QoL value to the
overall outcome of the different strategies depends on
the time spent in the health state.10 Two different treat-
ment strategies were assessed: OR and EV. The primary
outcome was QALYs. Secondary outcomes were total ex-
pected lifetime costs, cost-effectiveness of the different
treatment options, and expected reinterventions. Dataand probabilities to populate the decision model were
retrieved from a recent and extensive meta-analysis for
CMI, which provided a summary of best available current
evidence.11 The most contemporary data from this article
were used in the model. Variables that were not explicitly
reported in the meta-analysis were obtained by perform-
ing additional analyses of the original articles that were
used in the meta-analysis. The ranges of values of the vari-
ables derived from these articles were used to perform
one-way, two-way, and multi-way sensitivity analyses of
the model.
Decision model. In the model, all patients started
with an intervention (OR or EV, as determined by the
assigned treatment group) and transitioned to other health
states after this intervention. The possible transitions be-
tween the health states are shown in Fig 1. After an
intervention, patients could recover completely without
complications (well postoperative); they could have major,
long-term systemic complications (eg, stroke, renal failure
needing dialysis; major complications) or additional partial
bowel resection (bowel resection); or they could die (peri-
operative mortality; death). Bowel resection was a speciﬁc
health state that was not included in the major complica-
tions state because of its relevance to CMI. Once patients
entered into the major, long-term complications, they could
no longer regain good health status. Another possible
health state for the EV group after intervention was
conversion to OR.
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remain in this health state if the treated vessel remained
patent or if they were asymptomatic. If the patient became
symptomatic and an additional intervention on the treated
vessel was required, this could be either OR or EV. After
these interventions, the same health state options were
possible as after the initial intervention. Possible options
for patients in the bowel resection health state were the
same as for the well postoperative health state, and recurrent
mesenteric insufﬁciency subject to reintervention was also
possible. The last possible health state was the bowel
resection þ major complications health state for patients
who underwent bowel resection and suffered a major
complication.
The model cycled at 1-year intervals with a half-cycle
correction until all patients in the model were categorized
as dead. Half-cycle correction was applied to prevent over-
estimation or underestimation because most events gener-
ally do occur throughout a cycle and not only at the
beginning or end.12 To keep the model manageable, as-
sumptions were made:
1. No distinction was made between different types of
OR. In a report of 16,000 patients who underwent
OR for CMI, the majority were treated with bypass
(93%) compared with endarterectomy (4%) or embo-
lectomy (3%).7 No distinction was made between
different types of EV treatment.
2. Postoperative mortality was described as 30-day
mortality.
3. Loss of patency of the treated vessel during follow-up
was considered to be symptomatic and requiring a
reintervention.
4. Patency rates are not consistently described in the
literature, with some reports using either primary
assisted or secondary patency rates. We use the
term secondary patency rate to refer to either primary
assisted or secondary patency because the conse-
quences are similar.
5. Primary and secondary patency rates were assumed
to have a constant hazard rate after the ﬁfth year.
Only data from patients with classic presentation of
CMI were included; acute on chronic patients were
omitted from analysis.
Total QALYs for the different treatment groups were
calculated by the length of stay in a health state multiplied
by the QoL value for that speciﬁc health state. A discount
rate of 3% was applied to both costs and effectiveness to
adjust future effectiveness and costs because life-years and
cost in the near future are considered to have more value
than life-years and cost in the distant future.13
Interventions. Table I shows the probabilities for OR
and EV.11,14-23 To differentiate the impact of interventions
in low- and high-risk patients, perioperative mortality rates
were multiplied by relative risks (range, 0.5-5).
Patency. Patency rates were retrieved from a single
report20 that provided the best available evidence describingpatency rates for OR and EV in patients with CMI (Table II).
This study distinguished primary and secondary patency rates,
which is what is required for the model, whereas the pooled
patency rates reported in the meta-analysis11 combined pri-
mary assisted and secondary patency rates as if they were the
same outcome. Patency rates beyond 5 years were not re-
ported and were assumed to have a constant hazard rate. The
patency rates reported in the meta-analysis were used in a
sensitivity analysis on the patency rates.
Mortality. Age-, sex-, and race-speciﬁc mortality tables
for women and men were retrieved from the Centers for
Disease Control and Prevention.24 Because long-term
mortality rates for patients with CMI are higher compared
with the general population but are not reported, we made
an assumption and used the disease-speciﬁc mortality rate
for patients with peripheral arterial disease.15 Mortality rate
for patients with major morbidities was based on chronic
kidney disease.25
QoL. Because there are no studies describing QoL of
patients with CMI, QoL values for patients with choledo-
cholithiasis with severe pain were used.26 These patients
have similar symptoms (eg, postprandial pain) and were
assumed to have the same QoL. QoL values for major
complications caused by the interventions were assumed to
be similar to QoL values in patients with chronic kidney
disease (one of the major complications).27 The QoL value
for CMI patients after bowel resection was considered to
be similar to that for patients with colitis in remission, after
partial bowel resection and no symptoms.28
For the interventions, disutilities or tolls were included.
These disutilities were applied every time an intervention
was required and were based on the average recovery
time for these interventions. These tolls were supported
by the QoL adjustments of open and endovascular repair
of abdominal aortic aneurysms reported in the literature.29
For acute complications, a disutility of 0.02 QoL (com-
parable with 1 week in perfect health) was subtracted.
A wide range for all the QoL values (column 3, Table I)
was used to explore the effect of the assumptions and to
include the uncertainty around the input variables.
Costs. To evaluate the lifetime costs and cost-
effectiveness for both treatment strategies (OR and EV),
procedure and hospital costs, follow-up costs, and costs of
major complications were analyzed from a health care
perspective and were given in reimbursement amounts
to the physician and hospital rather than charges. First,
Current Procedural Terminology and Healthcare Common
Procedure Coding System codes were deﬁned for the
procedures (35531 [OR], 37205 [EV], 44120 [bowel
resection], and 99213 [follow-up]); reimbursement
amounts were retrieved by use of these codes and are shown
in Table III.30 We assumed that patients would not have
imaging during follow-up unless they were symptomatic.
Length of hospital stay was multiplied by the costs of
hospital stay per day to calculate the direct hospitalization
costs. Costs of hospitalization per day were derived from
published data on actual hospital costs and inﬂated to
2013 dollars through the medical component of the
Table I. Input variables for open revascularization (OR) and endovascular revascularization (EV) of chronic mesenteric
ischemia (CMI)
Variables Reference-case Range for sensitivity analysise References
OR
Technical success 95.1% 90%-100% 11
Perioperative mortality 7.08% 0%-13% 11
Minor/short-term complicationsa 30.3% 10%-50% 11
Major/long-term complicationsb 3.9% 1.0%-5.0% 11
Immediate conversion NA NA NA
Conversion rate/year NA NA NA
Reinterventions/year 1.9% 0.5%-3.0% 20
Endovascularc 50% 0%-100% 20
Opend 50% 0%-100% 20
Bowel resection 8.0% 2%-10% 14,18,19
Primary and secondary patency Table II NA 20
Mean hospitalization, days 18 7-30 11
EV
Technical success 93.2% 90%-98% 11
Perioperative mortality 3.62% 0%-6.0% 11
Minor/short-term complicationsa 11.2% 5%-20% 11
Major/long-term complicationsb 1.8% 1.0%-5.0% 11
Immediate conversion 2.9% 1.0%-5.0% 16,21
Conversion rate/year 3.6% 1.0%-6.0% 16,22
Reinterventions/year 13.9% 5.0%-15% 20
Endovascularc 88.5% 0%-100% 20
Opend 11.5% 0%-100% 20
Bowel resection 2.6% 1.0%-5.0% 21,23
Primary and secondary patency Table II NA 20
Mean hospitalization, days 4.5 2-10 11
General variables
Mortality bowel resection 27.9% 10%-40% 17
Major complications after bowel resectionb 7.2% 5.0%-15% 17
Standardized mortality rate for CMI 1.76 d 15
þ major morbidity 3.1 d 25
Discount rate 3% 0%-5% 13
QoL values
CMI 0.87 0.85-0.89 26
Well postoperative 0.90 0.88-0.92 26
Well after reintervention 0.90 0.88-0.92 26
After bowel resection 0.85 0.83-0.87 28
Major complicationsb 0.45 0.43-0.47 27
Major complications þ bowel resection 0.40 0.20-0.60 d
Dead 0 0 d
Impact of interventions (tolls) f
OR 0.08 0.16 to 0.04 29
EV 0.03 0.06 to 0.01 29
Bowel resection 0.12 0.14 to 0.11 d
Acute complication 0.02 0.04 to 0.01 d
NA, Not applicable; QoL, quality of life.
aMinor complications include infection, hemorrhage, acute renal failure, or other transient complications.
bMajor complications include chronic renal failure and chronic cardiopulmonary or cerebrovascular complications.
cEndovascular reinterventions include thrombolysis and percutaneous transluminal angioplasty with or without stenting.
dOpen reinterventions include bypass, embolectomy, endarterectomy, and bowel resection.
eRange tested in sensitivity analysis is a wide range to evaluate the impact of this variable on the outcomes of the model.
fNo references are used for disutilities for bowel resection.
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morbidity were retrieved from published literature
regarding the costs for chronic kidney disease, stage 3
(moderate, International Classiﬁcation of Diseases, Ninth
Revision code: 583.3). All the costs were tested over a
wide range with sensitivity analyses to include the uncer-
tainty around the variables.
Data analysis and reference-case. In the reference-
case analysis, 10,000 65-year-old female patients withCMI refractory to conservative management and average
risk for operation entered the model. Female patients were
chosen because 70% to 80% of all patients with CMI are
women and 65 years is the average age at intervention.32
Validation of the model was performed by comparing the
number of expected reinterventions for both procedures in
this model with the reported reinterventions from a recent
systematic review.32 An additional analysis was performed
for patients in whom bowel viability needed to be assessed
Table III. Codes and costs for interventions and comorbidities for the treatment of chronic mesenteric ischemia (CMI)
Variable HCPCS/CPT code Costs (2013 U.S. $)c Range References
OR 35531 $2108 $1581-$2635 30,d
EV 37205 $4563 $3422-$5703 30,d
Bowel resection 44120 $1228 $921-$1535 30,d
Follow-upa 99213 $73 $44-$143 30,d
Major complicationsb 583.3 $11,970/year $5000-$25,000 30,d
Hospital stay/day NA $1351 $1013-$1688 31
CPT, Current Procedural Terminology; EV, endovascular revascularization; HCPCS, Healthcare Common Procedure Coding System; NA, not applicable;
OR, open revascularization.
aTwo outpatient follow-up visits to a vascular surgeon in the ﬁrst year and one annual visit for later years.
bBased on costs for complication of chronic kidney disease, which is the most common major complication after revascularization for CMI.
cCosts are given in whole dollars.
dCPT and HCPCS codes were deﬁned for the procedures, and reimbursement amounts were retrieved by use of these codes with the Centers for Medicare and
Medicaid Services physician fee schedule (http://www.cms.gov/apps/physician-fee-schedule/), accessed June 1, 2013.
Table II. Patency rates for open revascularization (OR) and endovascular revascularization (EV) of chronic mesenteric
ischemia (CMI)
Type of revascularization Patency 1st year 2nd year 3rd year 4th year 5th year
OR Primary 94.0% 92.0% 92.0% 90.0% 88.0%
(94.2%) d d d (80.9%)
Secondary 99.0% 98.0% 98.0% 97.5% 97.0%
d d d d (97.9%)
EV Primary 67.0% 58.0% 53.0% 47.0% 41.0%
(71%) d d d (49.1%)
Secondary 91.0% 88.0% 88.0% 88.0% 87.5%
d d d d (88.0%)
Patency rates derived from Oderich et al20 (and Pecoraro et al,11 shown in parentheses).
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resection at all.
Calculation of the incremental cost-effectiveness ratio
(ICER) was performed by dividing the difference in costs
(in 2013 U.S. dollars) by the difference in effectiveness
(in QALYs). The willingness-to-pay threshold, which
is the maximum amount that society is willing to pay
for one additional year in perfect health, was set to
$60,000 per QALY and tested in sensitivity analysis
($0-$100,000).33
Sensitivity analyses were performed to assess the impact
of the variable values on the outcomes of the model.
A probabilistic sensitivity analysis using Monte Carlo simu-
lation was performed with 10,000 random samples12 to
assess the uncertainty around the variable values by distri-
butions of the values rather than deterministic values.
The type of distribution depended on the type of variable.
Beta distributions were used to model the probabilities of
events, parameterized by the total number of patients
and the number of patients with the event of interest.
Triangular distributions were used for utilities, parameter-
ized by the best available most likely, minimum and
maximum value for these utilities.12 A difference of less
than 0.1 QALY was considered indifferent. Outcomes aregiven with a 95% credibility interval (CI). CIs in Bayesian
approaches are analogous to conﬁdence intervals in fre-
quentist statistics.
RESULTS
Analysis of the reference-case (10,000 65-year-old
female patients with CMI refractory to conservative man-
agement and with an average risk for operation) revealed
that EV was the dominant strategy for patients with CMI
on the basis of higher QALYs and lower costs. Fig 2 shows
the results of probabilistic sensitivity analysis with 10,000
samples of the cost-effectiveness in a scatterplot. After
35 years of follow-up, when every patient had either died
or reached the age of 100 years, EV had 10.03 expected
QALYs (95% CI, 9.76-10.29) vs 9.59 (95% CI, 9.29-
9.87) for the OR group. There was a signiﬁcant difference
between the two strategies: 0.44 QALY (95% CI, 0.13-
0.76), which is comparable to an average difference of
5 months in perfect health. The total expected costs from
the health care perspective for the reference-case patient
were $39,942 (95% CI, $28,509-$53,380) for OR and
$38.217 (95% CI, $29,329-$48,309) for EV, with a differ-
ence of $1725 (95% CI, $7663 to $11,882) in favor
of EV.
Fig 3. Total expected quality-adjusted life-years (QALYs) for
open revascularization (OR) and endovascular revascularization
(EV), depending on age at initial intervention of chronic mesen-
teric ischemia (CMI) for the reference-case patients (65-year-old
women). See Results section for further details.
Fig 2. Cost-effectiveness scatterplot of open revascularization
(OR) and endovascular revascularization (EV) for treatment of
chronic mesenteric ischemia (CMI) for the reference-case patients
(65-year-old women). Each point represents one sample value
based on the analysis of 10,000 reference-case samples in the
Monte Carlo simulation. The results indicate that EV is dominant
over OR because effectiveness is higher and costs are lower. See
Results section for further details. QALYs, Quality-adjusted life
years.
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Cumulative expected QALYs for 65-year-old men in
the EV group were 8.71 (95% CI, 8.48-8.94) vs 8.42
(95% CI, 8.14-8.63) in the OR group. The total expected
costs for 65-year-old men were $39,375 (95% CI,
$28,092-$52,853) for OR and $35,903 (95% CI,
$27,685-$45,597) for EV. Differences between EV and
OR for QALYs and costs were 0.31 QALY (95% CI,
0.06-0.59) and $3472 (95% CI, $5874 to $13,799),
both in favor of EV.
Sensitivity analyses
Age. Fig 3 demonstrates that EV yielded higher
effectiveness in QALYs for all ages compared with OR,
with a difference ranging from 0.59 QALY (95% CI, 0.09-
1.04; at 50 years) to 0.13 QALY (95% CI, 0.07-0.17; at
95 years). As shown in Fig 3, the older the patient was at
the time of initial treatment, the smaller the beneﬁt of EV
in QALYs.
Risk proﬁle. Sensitivity analysis of different risk cate-
gories of patients revealed no change in preferred treatment
option based on QALYs. With use of relative risks for peri-
operative mortality, ranging from 0.5 (low risk) to 5 (very
high risk), EV remained the preferred treatment option for
all the different risk proﬁles (Supplementary Fig 1, online
only).
Perioperative mortality. Supplementary Fig 2, online
only, demonstrates that if open surgical techniques
improve and 30-day perioperative mortality for OR de-
creases to 3.1%, OR yields greater effectiveness in QALYs
compared with EV. This assumes the perioperative mor-
tality for EV is 3.6%. A two-way sensitivity analysis for
perioperative mortality of EV and OR is shown in
Supplementary Fig 3, online only.Reinterventions. Fig 4, a depicts that an initial
treatment with EV resulted in more reinterventions
compared with OR. For the 65-year-old reference-case
patients, 1.70 reinterventions per patient were expected
in the EV group compared with 0.32 per patient in the OR
group. Fig 4, b shows the number of reinterventions for
both treatment groups for patients ranging from 50 to
95 years of age. For 50-year-old patients, this was 2.68
(EV) and 0.56 (OR); and for 95-year-old patients, 0.26
(EV) and 0.05 (OR). For every age group, the number of
expected reinterventions was approximately ﬁve times
higher after EV compared with OR. These numbers were
the average for the whole group. Despite the signiﬁcantly
greater number of reinterventions that are accompanied by
more hospitalization periods, the QALYs were always
higher for patients treated with EV compared with OR.
Validation of the model, by comparing predicted rein-
terventions with reported reinterventions for EV and OR,
showed that EV has up to ﬁve times more expected reinter-
ventions compared with OR, similar to the 4.2-fold
increase reported.32
Costs. For patients between 50 and 60 years of age,
EV was more expensive compared with OR, mostly
because of the number of reinterventions and subsequent
hospitalization periods. After the age of 60 years, OR was
more expensive than EV (Fig 5). However, the ICER in-
dicates that for patients between 50 and 60 years of age,
costs and effectiveness are higher for EV, but the ICER is
still under the willingness-to-pay threshold of $60,000/
QALY (maximum $4780/QALY, at age 50 years), and
therefore EV is the preferred treatment option despite the
higher cost in this age group (Supplementary Fig 4, online
only). After the age of 60 years, costs for OR are higher
Fig 5. Total expected costs for open revascularization (OR) and
endovascular revascularization (EV) by age at initial intervention
for the reference-case patients (65-year-old women with chronic
mesenteric ischemia [CMI]). Shown is that EV is more expensive
until the age of 60 years. After the age of 60 years, OR is more
expensive. See Results section for further details.
Fig 6. The 95% conﬁdence ellipse for the cost-effectiveness of
endovascular revascularization (EV) vs open revascularization
(OR) for 10,000 samples of the reference-case patients (65-year-
old women with chronic mesenteric ischemia [CMI]). On the
x-axis, the incremental quality-adjusted life-years (QALYs) for EV
compared with OR. On the y-axis, the incremental costs for EV
compared with OR. For each of the 10,000 samples, the difference
between the QALYs (incremental QALYs) and the difference be-
tween the costs (incremental costs) for EV and OR are calculated
and depicted as a dot in the ﬁgure. The circle depicts 95% of the
distribution. The willingness-to-pay (WTP) of $60,000/QALY
is indicated. All dots southeast of the WTP line are considered
cost-effective.
Fig 4. a, Cumulative expected reinterventions per patient after
initial treatment of chronic mesenteric ischemia (CMI) for the
reference-case patients (65-year-old women). See Results section
for further details. b, Number of expected reinterventions
depending on the age at initial intervention for CMI for the
reference-case patients (65-year-old women). See Results section
for further details. EV, Endovascular revascularization; OR, open
revascularization.
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 3 Hogendoorn et al 721and effectiveness is lower, and therefore OR is dominated
by EV as the preferred treatment strategy.
Probabilistic sensitivity analysis. Use of a Monte
Carlo strategy selection with a willingness-to-pay
threshold of $60,000/QALY showed that EV was cost-
effective in 99.8% of the reference-case samples (Fig 6).
The cost-effectiveness acceptability curve (Fig 7) demon-
strates the robustness of the model. Even if the willingness-
to-pay threshold decreases, EV is in a higher percentage of
the cases more cost-effective compared with OR.
Length of hospital stay. Performance of a sensitivity
analysis on the postoperative hospitalization period forOR (18 days for the reference-case) showed that if the
hospitalization period was less than 16 days, OR had lower
expected costs for the reference-case patients. However,
the ICER still remains under the willingness-to-pay
threshold of $60,000/QALY, even if the postoperative
Fig 7. Acceptability curve for different willingness-to-pay
threshold points for the treatment of chronic mesenteric
ischemia (CMI). On the x-axis, the willingness-to-pay; and on the
y-axis, the percentage of samples that is cost-effective. Shown is
that even if the willingness-to-pay decreases to $0, endovascular
revascularization (EV) is cost-effective in the majority of the cases
compared with open revascularization (OR).
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(ICER, $40,333/QALY). This is based on the assumption
that the postoperative hospitalization period for EV
remained unchanged at 4.5 days (Supplementary Fig 5,
online only).
Bowel resection and sensitivity analyses. Additional
analysis on the chance of bowel resection showed that pa-
tients who underwent immediate bowel resection with OR
had decreased QALYs compared with patients who did not
undergo bowel resection at all (Supplementary Fig 6, on-
line only). EV was in both patient groups preferred to OR.
Performance of a sensitivity analysis on disutility values over
a wide range did not show a signiﬁcant effect on the initial
treatment choice (Supplementary Fig 7, online only). Use
of patency rates from the systematic review instead of the
large single-center study resulted in a small change in dif-
ference between the two strategies of 0.02 QALY in favor
of EV. We also assumed that 50% of reinterventions
after open treatment would be done by endovascular
means. This assumption was tested by a wide range
(0%-100%), but it did not change the preferred treatment
(Supplementary Fig 8, online only).
DISCUSSION
On the basis of the results of this decision analysis, EV
is the preferred treatment for patients with CMI refractory
to conservative management; the effectiveness of EV is
higher compared with OR for every age group and risk
proﬁle. Although EV has a ﬁvefold increase in expected
reinterventions compared with OR, total costs are lower
for patients 60 years or older. For patients younger than
60 years, the costs of EV are higher, but EV may still be
preferable to OR because the maximal ICER is $4780/
QALY, which is far under the willingness-to-pay threshold
of $60,000/QALY.The difference for the outcomes for the reference-case
65-year-old patient for EV over OR is signiﬁcant (0.44
QALY; 95% CI, 0.13-0.76) and equivalent to 5 months
in perfect health difference. For younger patients, this dif-
ference is larger, 0.59 QALY (95% CI, 0.09-1.04; at
50 years); and even for 95-year-old patients, EV dominates
(0.13 QALY; 95% CI, 0.07-0.17). This difference is the
average for the group, and so some patients may have
only a small beneﬁt and others will have a larger beneﬁt.
Total average expected costs for the complete group are
less for men compared with women, and this could be
explained by the fact that women have overall a higher
life expectancy at time of diagnosis. In other words, women
have more life-years ahead of them, resulting in more
follow-up visits and greater number of years at risk for com-
plications and subsequent reinterventions, which increases
the total costs. Additional analysis for patients with imme-
diate bowel resection after assessment of bowel viability
showed that these patients have lower QALYs compared
with patients in whom bowel resection was not necessary.
EV is the preferred treatment in both types of patients.
Decision analysis is a useful method to assess prognosis,
especially in diseases that involve transitions between health
states. Moreover, decision analysis can compare treatments
in the same patient through computer simulation, some-
thing that is impossible in a clinical trial. The strength of
decision models is sensitivity analysis: the effect of uncer-
tainty in the parameter values can be explored, and with
probabilistic sensitivity analysis, the effect of uncertainty
around a range of variables can be analyzed. Decision anal-
ysis combined with the increasing amount of available liter-
ature can play a major role in the development of
individualized medical decision-making because there is
no “one size ﬁts all” treatment for most vascular diseases.
Although decision models are useful to synthesize the
best available evidence, there are inherent limitations. First,
data are usually retrieved from published data, and in the
current study, they were extracted from a meta-analysis.
Analysis of the literature demonstrates heterogeneity of re-
ported outcomes and quality of reporting. In this regard,
probabilistic sensitivity analysis is one of the strengths of
our methodology because it is speciﬁcally designed for
when there is uncertainty around the variables. Second, as-
sumptions had to be incorporated into the model, but they
probably affect both EV and OR groups to a similar de-
gree. For example, we assigned empirical values for disutil-
ities for interventions, supported by reported disutilities in
the literature.29 However, when we tested disutility values
over a wide range with a sensitivity analysis, we found no
signiﬁcant effect on the initial treatment choice. For
example, OR for CMI is usually an aortaesuperior mesen-
teric artery bypass with vein or prosthetic graft. If the graft
occludes later during follow-up, a repeated aortaesuperior
mesenteric artery bypass is commonly performed.34 There-
fore, assuming that 50% of reinterventions after open CMI
treatment will be done by endovascular means may be
higher than what happens in practice. This assumption
was also tested by a wide range (0%-100%) and did not
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 3 Hogendoorn et al 723change the preferred treatment. Because of the use of
duplex or other modalities to detect restenosis and the rela-
tive ease of performing reinterventions with EV, the
threshold for repeated EV is likely to be signiﬁcantly lower
compared with OR. Furthermore, the data used for the
hospitalization period after OR or EV were retrieved
from a meta-analysis, but this may have included papers
from centers that had different interval dates of analysis
or degree of expertise or that were smaller centers. As a
result, the assumed hospitalization periods may have been
longer than currently practiced. This variable is recognized
as an important parameter in evaluating for costs, and so
extensive sensitivity analysis was performed on these vari-
ables without any change in the recommendation of EV
as preferred treatment for CMI (Supplementary Fig 5, on-
line only). Another limitation is the lack of data for some
input variables, speciﬁcally for patients with CMI, including
QoL values and mortality rates for patients with complica-
tions. Therefore, these variables were derived from articles
that were nonspeciﬁc for patients with CMI. However,
these variables were chosen because they are likely to be
close to the QoL values for patients with CMI who have
similar symptoms, such as postprandial pain. In addition,
these variables were tested with probabilistic sensitivity an-
alyses over a wide range to include the uncertainty around
these variables.
As stated previously, any change in input variables will
affect the outcome, and so the input variables were criti-
cally evaluated. For example, the codes and costs used to
calculate the total costs and cost-effectiveness of the EV
group were for stenting, not just for percutaneous translu-
minal angioplasty. Therefore, the real average costs for EV
may have been overestimated. In addition, because no
distinction was made between different types of EV, the
effectiveness for EV could have been even higher if we
had used only data of covered stents. Covered stents are
associated with less restenosis and fewer recurrences and
reinterventions, and they have a better primary patency af-
ter 3 years compared with bare metal stents and percuta-
neous transluminal angioplasty in patients undergoing
primary interventions or reinterventions for CMI.35
Furthermore, patients in the original articles that had pro-
vided data for the EV group included relatively older pa-
tients with more comorbidities.20 This probably
represents selection bias, EV being chosen in nonsurgical
candidates. As a result, some variables that were used
may have been relatively biased against the EV group.
Despite this, EV was still the preferred treatment for all
age groups in our decision model, demonstrating the
robustness of our results. The model was sensitive for
changes in the perioperative mortality for OR, but this
affected results only if the mortality after OR would be
lower than after endovascular repair, which would be
very unlikely in reality (Supplementary Fig 3, online only).
Although there are many articles describing outcomes
for patients treated for CMI, the limitation is that most ar-
ticles usually report on only one or two main outcomes.
Although overall survival, patency, and complications areimportant outcomes, QoL, reinterventions, risk proﬁle of
the patient, and costs are also clinically relevant. In addi-
tion, this is the ﬁrst article describing costs for the treat-
ment of CMI. Furthermore, this is the ﬁrst model-based
study analyzing outcomes for different modalities of treat-
ment of CMI. External validation showed results consistent
with those previously reported.32
This clinical decision model can be used as a guide for
the treatment of CMI and demonstrates that patients suit-
able for both OR and EV should be best managed with
EV. However, not all patients are suitable for both treatment
strategies, for example, because of anatomic limitations, sur-
gical access issues, or extensive plaque calciﬁcation. There-
fore, an individualized approach will still be needed, and
treatment should be tailored to the patient.
There is currently no level I evidence available for the
management of CMI. A well-conducted multicenter ran-
domized controlled trial could provide this evidence;
however, this would be impractical, expensive, and time-
consuming. Our current study indicates the utility of deci-
sion models in analyzing published studies to provide
comparative information on treatment options for diseases
that have risks that change over time.
CONCLUSIONS
We have demonstrated that EV is preferred to OR for
the treatment of patients with CMI refractory to conserva-
tive treatment. Although more reinterventions are ex-
pected for patients treated with EV, EV has higher
expected QALYs and appears to be cost-effective for all
age groups.
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at www.jvascsurg.org.DISCUSSIONDr John Hallett (Charleston, SC). First, let me thank the Pro-
gram Committee for the privilege to comment on this important
presentation. And thanks to Dr Hogendoorn, Dr Sumpio, and col-
leagues for allowing me to peruse their manuscript before their
presentation.
In the past 20 years, the improvements in mesenteric ultra-
sound and the wider use of computed tomography mesenteric
angiography have revealed the larger size of this vascular
“iceberg.” Chronic mesenteric ischemia is much more prevalent
that we imagined. This sophisticated analysis comes at a time
when we all need management guidance based on all the evidence.
Four general questions come to mind in reviewing any paper.
First, can one summarize the message clearly in a sentence or two?
Second, have the methods been appropriate, even innovative, in
deriving the conclusions? Third, does the information offer any-
thing new to help in the care of patients? And ﬁnally, what is
next? How do we use this information to advance the science
and care of our vascular patients?Before comment is made on these four general questions, let
us remember the remarkable evolution, in less than a century, of
the recognition and management of chronic mesenteric ischemia.
Mesenteric ischemia was ﬁrst recognized in the 15th century in
Florence, Italy. For the next four centuries, postmortem studies
stressed that the “pre-mortem diagnosis is impossible, the prog-
nosis hopeless, and the treatment almost useless.”
In 1936, Dunphy, a Harvard surgical resident, made the
prescient observation that many patients who died of ischemic
gut infarction due to superior mesenteric artery (SMA) athero-
sclerosis had a typical history of postprandial abdominal pain
that was not called “intestinal angina” until 1956. In 1958,
Shaw at the Massachusetts General Hospital performed the ﬁrst
successful surgical SMA thromboendarterectomy. Subsequently,
Morris in Houston performed the ﬁrst successful surgical
bypass to the SMA in 1962. Working in San Francisco, Stoney
and Wylie perfected the transaortic thromboendarterectomy
by 1966.
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ment in the 1980s with their observation that long-term results
appeared better when more than one diseased mesenteric was
revascularized.
In 1980, Ferrer and Gruntzig reported the ﬁrst endovascular
dilation of the SMA.
All of these contributions over time must be considered as we
look at the currently proposed Markov decision model.
Now we come to the answers to the four key questions.
The single most important message from this sophisticated
study is that endovascular therapy is preferable in both effec-
tiveness and cost to surgical intervention at nearly every age.
Endovascular therapy has ﬁve times the rate of reintervention,
but this appears to be a reasonable tradeoff, considering the
relatively high mortality and morbidity of mesenteric artery
surgery.
Second, the Markov decision model is a proven method for
offering clinicians some guidelines about any intervention, at
various ages and with various risk factors. This model appears to
support the clinical observation and shifts in mesenteric therapy
that we have experienced in the past decade.
Third, this current model should help us all to inform our pa-
tients about the safer options for chronic mesenteric ischemia. But
in the end, I worry whether every vascular program will continue
to have a team capable of both endovascular therapy and surgical
intervention. We still need both options. Both require some
advanced skills that need to be focused on a few physicians and sur-
geons who do this frequently.
Finally, what is next? Could the authors comment on the
following?1. Is there enough data coming forward to ascertain when stent
angioplasty should be used over simple angioplasty? And, what
stent?
2. Do you really recommend that we consider a multicenter ran-
domized trial to evaluate angioplasty vs surgical revasculariza-
tion? That would be a very expensive and time-consuming trial.
3. Would it not be more reasonable to recommend that the
Vascular Quality Initiative consider a module to track the
treatment of both acute and chronic mesenteric ischemia
and outcomes? We would learn quickly what is really working.
Again, we all should appreciate the important value of this
Markov model in providing rational guidance in the management
of the increasingly recognized cases of chronic mesenteric
ischemia. The Medicare population doubles in the next decade,
and this challenging clinical entity is likely to be at our doorstep
ever more frequently.
Dr Wouter Hogendoorn. Thank you for your comments
and interesting questions. I also thank you for the historical over-
view. First, decision analysis is particularly useful when there is a lot
of clinical data but from small studies and when there are no ran-
domized controlled trials to guide treatment. Decision models
analyze the outcomes from these small studies and can provide
useful information for a speciﬁc patient on the basis of his or her
risk proﬁle. We envision the potential of creating an app or a chart
where this information can be stored and used by the surgeon and
patient to predict outcomes for the various treatment options.
Last, we agree that performing a randomized controlled trial is
difﬁcult and costly, and decision analysis may be the optimum
method for use of the clinical data that is already available.
Supplementary Fig 1 (online only). Total quality-adjusted life-
years (QALYs) for treatment of chronic mesenteric ischemia
(CMI) in the reference-case patient with open revascularization
(OR) and endovascular revascularization (EV) for different relative
risks. Expected QALYs for EV are always higher, independent of
the relative risk.
Supplementary Fig 2 (online only). Total quality-adjusted life-
years (QALYs) for treatment of chronic mesenteric ischemia
(CMI) in the reference-case patient with open revascularization
(OR) and endovascular revascularization (EV) per perioperative
mortality for OR. Expected QALYs for OR are higher if periop-
erative mortality of OR decreases to 3.1% (in reference-case: 7.1%),
if we assume that perioperative mortality for EV is still 3.6%.
Supplementary Fig 3 (online only). Two-way sensitivity analysis
for perioperative mortality for endovascular revascularization (EV)
and open revascularization (OR). The colored areas indicate which
treatment is preferred on the basis of quality-adjusted life-years
(QALYs). The reference-case is indicated with an asterisk: peri-
operative mortality of 7.1% for OR and 3.6% for EV.
Supplementary Fig 4 (online only). Incremental cost-effectiveness
ratio (ICER) for treatment of chronic mesenteric ischemia (CMI) in
the reference-case patient per age at initial intervention. The ICER
of endovascular revascularization (EV) vs open revascularization
(OR) had a maximum at age 50 years: $4032 per quality-adjusted
life-year (QALY). After the age of 60 years, costs for EV are lower
and QALYs are higher, implying that EV dominates OR.
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Supplementary Fig 6 (online only). Total quality-adjusted life-
years (QALYs) for patients with and without bowel resection. For
patients with immediate bowel resection (100% chance) for
chronic mesenteric ischemia (CMI), the QALYs are lower
compared with patients without (0%) bowel resection. EV,
Endovascular revascularization; OR, open revascularization.
Supplementary Fig 5 (online only). Incremental cost-effectiveness
ratio (ICER) for treatment of chronic mesenteric ischemia (CMI) in
the reference-case patient per length of postoperative period for
open revascularization (OR). The ICER of endovascular revascu-
larization (EV) vs OR is always below the willingness-to-pay
threshold of $60,000/QALY. A longer hospitalization period than
16 days for OR results in lower costs for EV and higher quality-
adjusted life-years (QALYs), implying that EV dominates OR.
Supplementary Fig 7 (online only). Total quality-adjusted life-
years (QALYs) per quality of life for major morbidities for treat-
ment of chronic mesenteric ischemia (CMI) in the reference-case
patient with open revascularization (OR) and endovascular revas-
cularization (EV). Expected QALYs for EV are always higher than
for stenting and OR, regardless of the value of the quality of life for
major morbidities.
Supplementary Fig 8 (online only). Total quality-adjusted life-
years (QALYs) for the treatment of chronic mesenteric ischemia
(CMI) in the reference-case patient if type of reintervention after
initial open revascularization (OR) is endovascular revasculariza-
tion (EV), tested over a wide range (0%-100%).
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